Breath testing for gastric cancer screening
Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach
This study is testing if breath tests can help find gastric cancer and related conditions in people who have cancer, precancerous lesions, or are at average risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Latvia Academic / other |
| Locations | 5 sites (São Paulo and 4 other locations) |
| Trial ID | NCT04022109 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of volatile organic compound (VOC) testing in screening for gastric cancer and related conditions. It will enroll patients with established gastric cancer, precancerous lesions, and individuals from the general population at average risk. The study will utilize gas chromatography coupled with mass spectroscopy and sensor technology to analyze breath samples for VOCs. Additionally, it will investigate the influence of lifestyle factors and microbiota on VOC composition.
Who should consider this trial
Good fit: Ideal candidates include patients with verified gastric cancer, those undergoing upper endoscopy, and average-risk individuals aged 40-64 without alarm symptoms.
Not a fit: Patients with other active cancers or those unable to cooperate due to ventilation problems may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method for early detection of gastric cancer, potentially improving patient outcomes.
How similar studies have performed: Other studies have explored breath testing for cancer detection, showing promise, but this specific approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with verified gastric cancer (Group 1 \& 2) * Patients undergoing or having undergone upper endoscopy according to clinical indications (Group 3 \& 5) * Average-risk population group aged 40-64 at inclusion without alarm symptoms (Group 4) * Motivation to participate in the study * Physical status allowing volatile marker sampling and other procedures within the protocol * Signed consent Exclusion Criteria: * Known other active cancer * Ventilation problems, airway obstruction * Unwillingness or inability to co-operate
Where this trial is running
São Paulo and 4 other locations
- A.C.Camargo Cancer Center — São Paulo, Brazil (Recruiting)
- Pontificia Universidad Catolica de Chile — Santiago, Chile (Not_yet_recruiting)
- Centro Javeriano de Oncología, San Ignacio University Hospital — Bogotá, Colombia (Not_yet_recruiting)
- Institute of Clinical and Preventive Medicine, University of Latvia — Riga, Latvia (Recruiting)
- National Cancer Institute of Ukraine — Kiev, Ukraine (Recruiting)
Study contacts
- Principal investigator: Hossam Haick, PhD — TECHNION, Israel Institute for Technology
- Study coordinator: Marcis Leja, MD, PhD
- Email: marcis.leja@lu.lv
- Phone: +37129497500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.